Viemed Healthcare Announces Recent Publication of Non-invasive Ventilation Study
January 07 2021 - 8:00AM
Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO
and NASDAQ:VMD), a home medical equipment supplier that provides
post-acute respiratory care services in the United States,
announced a recently completed non-invasive ventilation study led
by Dr. William Frazier, Viemed’s Chief Medical Officer. The study,
entitled “Non-invasive Ventilation at Home Improves Survival and
Decreases Healthcare Utilization in Medicare Beneficiaries with
Chronic Obstructive Pulmonary Disease with Chronic Respiratory
Failure,” has been published online
(https://doi.org/10.1016/j.rmed.2020.106291) and in print by the
peer reviewed journal, Respiratory Medicine. This first of its kind
investigation was performed in conjunction with Precision Health
Economics, a leading bio-statistical and analytics firm.
The study evaluated clinical outcomes in COPD
patients with chronic respiratory failure (COPD-CRF) treated with
non-invasive ventilation at home (NIVH) compared to similar
patients with COPD-CRF who did not receive NIVH. The treatment and
control groups were closely matched on a multitude of clinical and
demographic variables and were statistically identical.
The highlights of the results, all of which were
highly statistically significant, are as follows:
- The group treated with NIVH had a
50% decrease in all-cause mortality during the study period
- The group treated with NIVH had a
28% decline in the risk of hospitalization
- The group treated with NIVH had a
52% reduction in the risk of an emergency room visit
All data for the study was obtained from the
Medicare Limited Data Set and included patients who were diagnosed
with COPD and CRF between 2012 and 2018.
“This study is the first of its kind published
in the U.S. and represents a significant milestone in our mission
of educating the medical community on the benefits of NIVH,” said
Casey Hoyt, Viemed CEO. “The data supports that NIVH is the best in
class treatment for chronic respiratory failure consequent to COPD.
We are excited to share the results of this study with not only our
physician referral sources but with our colleagues and payors
throughout the industry.”
ABOUT VIEMED HEALTHCARE, INC.
Viemed, through its indirect wholly-owned
subsidiaries Sleep Management, L.L.C. and Home Sleep Delivered,
L.L.C., is a home medical equipment supplier that provides
post-acute respiratory care services in the United States. Sleep
Management, L.L.C. focuses on disease management and improving the
quality of life for respiratory patients through clinical
excellence, education, and technology. Its service offerings are
based on effective home treatment with respiratory care
practitioners providing therapy and counseling to patients in their
homes using cutting edge technology. Home Sleep Delivered, L.L.C.
focuses on providing in-home sleep testing for sleep apnea
sufferers. Visit our website at www.viemed.com.
For further information, please contact:
Glen AkselrodBristol Capital905-326-1888glen@bristolir.com
Todd ZehnderChief Operating OfficerViemed Healthcare,
Inc.337-504-3802investorinfo@viemed.com
Forward-Looking Statements
Certain statements contained in this press
release may constitute “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 or “forward-looking information” as such term is defined in
applicable Canadian securities legislation (collectively,
“forward-looking statements”). Often, but not always,
forward-looking statements can be identified by the use of words
such as “plans”, “expects”, “is expected”, “budget”, “potential”,
“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”,
“believes”, “projects”, or the negatives thereof or variations of
such words and phrases or statements that certain actions, events
or results “will”, “should”, “may”, “could”, “would”, “might” or
“will be taken”, “occur” or “be achieved” or the negative of these
terms or comparable terminology. All statements other than
statements of historical fact, including those that express, or
involve discussions as to, expectations, beliefs, plans,
objectives, assumptions or future events or performance, including
the benefits of NIVH for COPD patients with chronic respiratory
failure and the Company’s expectations regarding the recently
published study on the education of the medical community, are not
historical facts and may be forward-looking statements and may
involve estimates, assumptions and uncertainties that could cause
actual results or outcomes to differ materially from those
expressed in the forward-looking statements. Such statements
reflect the Company's current views and intentions with respect to
future events, and current information available to the Company,
and are subject to certain risks, uncertainties and assumptions.
Many factors could cause the actual results, performance or
achievements that may be expressed or implied by such
forward-looking statements to vary from those described herein
should one or more of these risks or uncertainties materialize.
These factors include, without limitation: the general business,
market and economic conditions in the regions in which the Company
operates; the impact of the COVID-19 pandemic and the actions taken
by governmental authorities, individuals and companies in response
to the pandemic on our business, financial condition and results of
operations, including on the Company's patient base and revenues,
employees, and equipment and supplies; the Company may be subject
to significant capital requirements and operating risks; the
ability of the Company to implement business strategies and pursue
business opportunities; volatility in the market price of shares in
the capital of the Company; the Company’s novel business model; the
risk that the clinical application of treatments that demonstrate
positive results in a study may not be positively replicated or
that such test results may not be predictive of actual treatment
results or may not result in the adoption of such treatments by
providers; the state of the capital markets; the availability of
funds and resources to pursue operations; decline of reimbursement
rates; dependence on few payors; possible new drug discoveries;
dependence on key suppliers; granting of permits and licenses in a
highly regulated business; competition; low profit market segments;
disruptions in or attacks (including cyber-attacks) on the
Company's information technology, internet, network access or other
voice or data communications systems or services; the evolution of
various types of fraud or other criminal behavior to which the
Company is exposed; the failure of third parties to comply with
their obligations; difficulty integrating newly acquired
businesses; the impact of new and changes to, or application of,
current laws and regulations; the overall difficult litigation and
regulatory environment; increased competition; changes in foreign
currency rates; increased funding costs and market volatility due
to market illiquidity and competition for funding; critical
accounting estimates and changes to accounting standards, policies,
and methods used by the Company; the impact of the previously
disclosed restatement and correction of the Company’s previously
issued financial statements; the previously disclosed identified
material weakness in the Company’s internal control over financial
reporting and the Company’s ability to remediate that material
weakness; the initiation of legal or regulatory proceedings with
respect to the restatement and corrections; the adverse effects on
the Company’s business, results of operations, financial condition
and stock price, as a result of the restatement and correction
process; the Company’s status as an emerging growth company and a
foreign private issuer; and the occurrence of natural and unnatural
catastrophic events or health epidemics or concerns, such as the
recent COVID-19 pandemic, and claims resulting from such events or
concerns; as well as those risk factors discussed or referred to in
the Company’s disclosure documents filed with the U.S. Securities
and Exchange Commission (the “SEC”) available on the SEC’s website
at www.sec.gov, including the Company’s most recent Annual Report
on Form 10-K and Quarterly Report on Form 10-Q, and with the
securities regulatory authorities in certain provinces of Canada
available at www.sedar.com. Should any factor affect the Company in
an unexpected manner, or should assumptions underlying the
forward-looking statements prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking statements are expressly qualified in
their entirety by this cautionary statement. Moreover, the Company
does not assume responsibility for the accuracy or completeness of
such forward-looking statements. The forward-looking statements
included in this press release are made as of the date of this
press release and the Company undertakes no obligation to publicly
update or revise any forward-looking statements, other than as
required by applicable law.
VieMed Healthcare (NASDAQ:VMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
VieMed Healthcare (NASDAQ:VMD)
Historical Stock Chart
From Sep 2023 to Sep 2024